Alessandro Floridi
Research Subjects
Alessandro Floridi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Alice Tantucci
S&R Farmaceutici S.p.A., Perugia, Italy
1 shared publicationAndrea Lazzarini
Laboratory of Nuclear Lipid BioPathology, CRABiON, 06100 Perugia, Italy ; Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy
1 shared publication- Andrea Lazzarini
S&R Farmaceutici S.p.A., Perugia, Italy
1 shared publication - Annamaria Porreca
Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, 00163 Rome, Italy
1 shared publication - Asiya Kamber Zaidi
ENT Surgeon and Research Fellow, Associazione Naso Sano, Italy
1 shared publication - Bernard Fioretti
Department of Chemistry, Biology and Biotechnologies, University of Perugia, 06123 Perugia, Italy
1 shared publication
Latest Publications
- Open Access
Antibody persistency and trend post-SARS-CoV-2 infection at eight months
An improved understanding of the immunity offered by the antibodies developed against SARS-CoV-2 is critical for the development of diagnostic tests and vaccines. Our study aimed at the longitudinal analysis of antibody presence, persistence and its trend over a period of eight months in a group of COVID-19 recovered patients who tested positive by real-time quantitative PCR for SARS-CoV-2 in the period between the 18th and 30th of March, 2020. The subjects were divided into two groups based on disease severity: mild and moderately-severe. The MAGLUMI 2019-nCoV lgM/lgG chemiluminescent analytical system (CLIA) assay was used to analyse the antibody titres. Robust IgG antibody persistency was demonstrated in 76.7 % of the subjects (23 out of 30) at eight months post-infection. The results of this study highlight an important point in terms of the association between humoral immune response and disease severity. Patients who might have experienced a relatively moderate-severe infection may develop a robust immunity that could persist for a longer duration.
Open AccessAntibody persistency and trend post-SARS-CoV-2 infection at eight months
An improved understanding of the immunity offered by the antibodies developed against SARS-CoV-2 is critical for the development of diagnostic tests and vaccines. Our study aimed at the longitudinal analysis of antibody presence, persistence and its trend over a period of eight months in a group of COVID-19 recovered patients who tested positive by real-time quantitative PCR for SARS-CoV-2 in the period between the 18th and 30th of March, 2020. The subjects were divided into two groups based on disease severity: mild and moderately-severe. The MAGLUMI 2019-nCoV lgM/lgG chemiluminescent analytical system (CLIA) assay was used to analyse the antibody titres. Robust IgG antibody persistency was demonstrated in 76.7 % of the subjects (23 out of 30) at eight months post-infection. The results of this study highlight an important point in terms of the association between humoral immune response and disease severity. Patients who might have experienced a relatively moderate-severe infection may develop a robust immunity that could persist for a longer duration.
- Open Access
- 13 November 2020
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 7
Resveratrol Supported on Magnesium DiHydroxide (Resv@MDH) Represents an Oral Formulation of Resveratrol With Better Gastric Absorption and Bioavailability Respect to Pure Resveratrol
Resveratrol attracts great interest because of the plethora of in vitro effects at the micromolar concentration range. Unfortunately, these effects are difficult to establish in vivo, due to the low concentration of resveratrol reached. This discrepancy is due to the molecules low solubility in water that favors the propensity for an intestinal absorption rather than in the gastric compartment. To address these challenges, we developed a Solid Dispersion of Resveratrol Supported by Magnesium Di Hydroxide formulation (Resv@MDH). This formulation displays increased water solubility and better bioavailability relative to pure resveratrol in the rabbit animal model. In our study, we evaluated the pharmacokinetics profile of resveratrol in six healthy human subjects following 180 mg of oral resveratrol administration, derived from Resv@MDH or pure resveratrol. Free resveratrol was evaluated in the whole blood sample by using HPLC - MS/MS. In comparison with pure resveratrol that displays an increase of the maximum plasma concentration, Cmax at about 90 min and 2 μM, Resv@MDH displays an earlier peak of resveratrol concentration with an increase of Cmax at about 30 min and 6 μM. The different kinetics suggest a main gastric route for resveratrol absorption from Resv@MDH, where, because of its improved dissolution rate, there seems to be a higher propensity for an acidic environment, as opposed to that with pure resveratrol. This conclusion is also supported by the numerical simulation analysis, which considers the principal steps during the oral route administration. Moreover, there is a 2-fold increase in the amount of free resveratrol with respect to pure resveratrol confirming a better bioavailability observed in the animal model. The characteristic feature of the pharmacokinetic profile of Resv@MDH implies that the beneficial properties of resveratrol in human health should be capitalized on it.
- 13 November 2020
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 7
Open AccessResveratrol Supported on Magnesium DiHydroxide (Resv@MDH) Represents an Oral Formulation of Resveratrol With Better Gastric Absorption and Bioavailability Respect to Pure Resveratrol
Resveratrol attracts great interest because of the plethora of in vitro effects at the micromolar concentration range. Unfortunately, these effects are difficult to establish in vivo, due to the low concentration of resveratrol reached. This discrepancy is due to the molecules low solubility in water that favors the propensity for an intestinal absorption rather than in the gastric compartment. To address these challenges, we developed a Solid Dispersion of Resveratrol Supported by Magnesium Di Hydroxide formulation (Resv@MDH). This formulation displays increased water solubility and better bioavailability relative to pure resveratrol in the rabbit animal model. In our study, we evaluated the pharmacokinetics profile of resveratrol in six healthy human subjects following 180 mg of oral resveratrol administration, derived from Resv@MDH or pure resveratrol. Free resveratrol was evaluated in the whole blood sample by using HPLC - MS/MS. In comparison with pure resveratrol that displays an increase of the maximum plasma concentration, Cmax at about 90 min and 2 μM, Resv@MDH displays an earlier peak of resveratrol concentration with an increase of Cmax at about 30 min and 6 μM. The different kinetics suggest a main gastric route for resveratrol absorption from Resv@MDH, where, because of its improved dissolution rate, there seems to be a higher propensity for an acidic environment, as opposed to that with pure resveratrol. This conclusion is also supported by the numerical simulation analysis, which considers the principal steps during the oral route administration. Moreover, there is a 2-fold increase in the amount of free resveratrol with respect to pure resveratrol confirming a better bioavailability observed in the animal model. The characteristic feature of the pharmacokinetic profile of Resv@MDH implies that the beneficial properties of resveratrol in human health should be capitalized on it.
- Open Access
- 1 January 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-5
How Microgravity Changes Galectin-3 in Thyroid Follicles
After long-term exposure to real microgravity thyroid glandin vivoundergoes specific changes, follicles are made up of larger thyrocytes that produce more cAMP and express more thyrotropin-receptor, caveolin-1, and sphingomyelinase and sphingomyelin-synthase; parafollicular spaces lose C cells with consequent reduction of calcitonin production. Here we studied four immunohistochemical tumor markers (HBME-1, MIB-1, CK19, and Galectin-3) in thyroid of mice housed in the Mouse Drawer System and maintained for 90 days in the International Space Station. Results showed that MIB-1 proliferative index and CK19 are negative whereas HBME-1 and Galectin-3 are overexpressed. The positivity of Galectin-3 deserves attention not only for its expression but also and especially for its localization. Our results highlighted that, in microgravity conditions, Galectin-3 leaves thyrocytes and diffuses in colloid. It is possible that the gravity force contributes to the maintenance of the distribution of the molecules in both basal membrane side and apical membrane side and that the microgravity facilitates slippage of Galectin-3 in colloid probably due to membrane remodelling-microgravity induced.
- 1 January 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-5
Open AccessHow Microgravity Changes Galectin-3 in Thyroid Follicles
After long-term exposure to real microgravity thyroid glandin vivoundergoes specific changes, follicles are made up of larger thyrocytes that produce more cAMP and express more thyrotropin-receptor, caveolin-1, and sphingomyelinase and sphingomyelin-synthase; parafollicular spaces lose C cells with consequent reduction of calcitonin production. Here we studied four immunohistochemical tumor markers (HBME-1, MIB-1, CK19, and Galectin-3) in thyroid of mice housed in the Mouse Drawer System and maintained for 90 days in the International Space Station. Results showed that MIB-1 proliferative index and CK19 are negative whereas HBME-1 and Galectin-3 are overexpressed. The positivity of Galectin-3 deserves attention not only for its expression but also and especially for its localization. Our results highlighted that, in microgravity conditions, Galectin-3 leaves thyrocytes and diffuses in colloid. It is possible that the gravity force contributes to the maintenance of the distribution of the molecules in both basal membrane side and apical membrane side and that the microgravity facilitates slippage of Galectin-3 in colloid probably due to membrane remodelling-microgravity induced.
- 1 October 1996
- Published by Elsevier in Clinica Chimica Acta
- Vol. 254 (2) , 149-157
Formylcolchicine bound to lactosaminated serum albumin is a more active antifibrotic agent than free colchicine
- 1 October 1996
- Published by Elsevier in Clinica Chimica Acta
- Vol. 254 (2) , 149-157
Formylcolchicine bound to lactosaminated serum albumin is a more active antifibrotic agent than free colchicine